SCHEMBL1500952

SCHEMBL1500952

O=S(=O)(Cl)c1ccccc1OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
MAPK1 P28482 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
ALPG P10696 1/20 0.47
PTK2B Q14289 1/20 0.47
HTR1A P08908 1/20 0.47
DRD2 P14416 1/20 0.47
CCNB2 O95067 1/20 0.46
CDK1 P06493 1/20 0.46
CDK4 P11802 1/20 0.46
CCNB1 P14635 1/20 0.46
CCND1 P24385 1/20 0.46
CCNB3 Q8WWL7 1/20 0.46
LIPE Q05469 1/20 0.46
MGLL Q99685 1/20 0.46
MAPK14 Q16539 2/20 0.45
LTA4H P09960 1/20 0.45
ACLY P53396 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6749805 0.90 MEN1 (0.48) MAPTL3MBTL1MAPK1TDP1HPGD
SCHEMBL6745587 0.86 FFAR1 (0.48) MAPTL3MBTL1MAPK1TDP1HPGD
SCHEMBL7108877 0.85 MAPT (0.53) MAPTL3MBTL1MAPK1TDP1ALPG
SCHEMBL5679038 0.83 CA1 (0.46) HPGDCA1CA2CA9CA12
SCHEMBL1028419 0.82 ALPG (0.51) MAPTL3MBTL1MAPK1TDP1ALPG
SCHEMBL4164605 0.82 MAPT (0.55) MAPTL3MBTL1MAPK1TDP1ALPG
SCHEMBL1013565 0.82 CA1 (0.56) MAPTL3MBTL1MAPK1TDP1ALPG
SCHEMBL27688885 0.81 PTGER1 (0.47) MAPTL3MBTL1MAPK1TDP1PTGER1
SCHEMBL7267144 0.81 MAPT (0.49) MAPTL3MBTL1MAPK1TDP1ALPG
SCHEMBL14842559 0.80 FABP4 (0.50) MAPTL3MBTL1MAPK1TDP1ALPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122182-A1 MYST Inhibitors Isosterix, Inc. 2025-04-17 US disclosed
EP-1892239-B1 Inhibitors of cytosolic phospholipase A2 WYETH LLC (US) 2013-02-20 EP disclosed
CN-101628888-B Inhibitors of cytosolic phospholipase a2 WYETH CORP 2012-05-23 CN disclosed
US-8163773-B2 Organic compounds NOVARTIS AG (CH) 2012-04-24 US disclosed
US-7906548-B2 Methods for the use of inhibitors of cytosolic phospholipase A2 WYETH LLC (US) 2011-03-15 US disclosed
US-7713964-B2 Methods for treating asthmatic conditions WYETH LLC (US) 2010-05-11 US disclosed
US-20100035957-A1 Methods for the Use of Inhibitors of Cytosolic Phospholipase A2 WYETH 2010-02-11 US disclosed
CN-101628888-A Inhibitors of cytosolic phospholipase A2 WYETH CORP 2010-01-20 CN disclosed
US-7605156-B2 Methods for the use of inhibitors of cytosolic phospholipase A2 WYETH (US) 2009-10-20 US disclosed
US-20090233920-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-09-17 US disclosed
EP-0934291-A4 SMITHKLINE BEECHAM CORP (US) 1999-08-11 EP disclosed
EP-0934291-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1999-08-11 EP disclosed
CN-1207095-A Protease inhibitors SMITHKLINE BEECHAM CORP (US) 1999-02-03 CN disclosed
EP-0687253-B1 4-AMINOPYRIDINES, PROCESS FOR PREPARING THE SAME AND MEDICAMENTS CONTAINING THE SAME BOEHRINGER MANNHEIM GMBH (DE) 1998-12-16 EP disclosed
WO-1997016433-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1997-05-09 WO disclosed
CN-1119858-A Aminopyridines, process for their preparation and pharmaceutical compositions containing them BOEHRINGER MANNHEIM GMBH (DE) 1996-04-03 CN disclosed
EP-0687253-A1 NEW 4-AMINOPYRIDINES, PROCESS FOR PREPARING THE SAME AND MEDICAMENTS CONTAINING THE SAME Roche Diagnostics GmbH (DE) 1995-12-20 EP disclosed
WO-1994020467-A1 NEW 4-AMINOPYRIDINES, PROCESS FOR PREPARING THE SAME AND MEDICAMENTS CONTAINING THE SAME BOEHRINGER MANNHEIM GMBH (DE) 1994-09-15 WO disclosed
US-4829079-A AMNESIA ROUSSEL UCLAF (FR) 1989-05-09 US disclosed
US-4425153-A Herbicidal sulfonamides E. I. DU PONT DE NEMOURS & CO. (US) 1984-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233920-A1 ORGANIC COMPOUNDS REN, ACE, AGTR1 MAPT 1008/4885L3MBTL1 3191/4885MAPK1 3136/4885
US-20250122182-A1 MYST Inhibitors MNAT1, SUGT1, ACAT2 MAPT 476/4885L3MBTL1 1245/4885MAPK1 1355/4885
US-20100035957-A1 Methods for the Use of Inhibitors of Cytosolic Phospholipase A2 PLA2G4A, PLA2G4B, PLA2G1B MAPT 3957/4885L3MBTL1 3369/4885MAPK1 1566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.